Foundation Year Pharmacy – Clinical Practice Test

Clinically significant interactions happen when one drug markedly changes the level or effect of another, either by altering metabolism/clearance (pharmacokinetic) or by producing a harmful additive effect (pharmacodynamic). The pairing of clarithromycin with ramipril does not create such a risk because ramipril is activated by esterases and not by CYP enzymes that clarithromycin inhibits, and there isn’t a shared adverse-effect threat that would be amplified here. In contrast, digoxin with amiodarone is a known interaction that raises digoxin levels and toxicity risk; lithium with bendroflumethiazide increases lithium levels and toxicity risk; while warfarin with ramipril is generally safe but can require monitoring due to individual variability. Therefore, clarithromycin with ramipril does not lead to a clinically significant interaction.